--- title: "Weekly Recap | Hims & Hers Health -14.62%, mired in regulatory and legal pressure" type: "News" locale: "en" url: "https://longbridge.com/en/news/297388588.md" description: "Hims & Hers Health (HIMS.US) fell 14.62% this week to close at $28.84, underperforming the S&P 500, which rose 0.49%, by about 15.11 percentage points. The week moved in one direction: Monday opened at $32.44 and the price slid most days, hitting an intraday low of $28.52 on Friday, which fell 8.9% on the day. The week’s amplitude was 12.95%. Total volume came to 59.44m shares, averaging about 11.89m a day, roughly 14." datetime: "2026-08-29T05:45:07.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/297388588.md) - [en](https://longbridge.com/en/news/297388588.md) - [zh-HK](https://longbridge.com/zh-HK/news/297388588.md) generator: "portal-rs" --- # Weekly Recap | Hims & Hers Health -14.62%, mired in regulatory and legal pressure ## The Week Hims & Hers Health (HIMS.US) fell 14.62% this week to close at $28.84, underperforming the S&P 500, which rose 0.49%, by about 15.11 percentage points. The week moved in one direction: Monday opened at $32.44 and the price slid most days, hitting an intraday low of $28.52 on Friday, which fell 8.9% on the day. The week’s amplitude was 12.95%. Total volume came to 59.44m shares, averaging about 11.89m a day, roughly 14.9% below the 60-day median daily volume, so the sell-off was relatively quiet on turnover. ## Key Events The main thread this week was regulatory and compliance risk. On Monday after the close, law firm Kessler Topaz Meltzer & Check announced an investigation on behalf of investors over FTC privacy allegations, and Visa placed the company on a monitoring list over billing disputes. On Tuesday the FTC sued over allegedly deceptive subscription practices, and with Visa’s move still in view, the stock fell about 10%. On Wednesday the National Advertising Division reached a split decision in a hair-care ad dispute between Kenvue and Hims & Hers, though attention stayed on the regulatory side. After a 6% bounce on Thursday, the stock fell 8% on Friday on news of a fraud probe and continued Visa monitoring, with late-week reports also mentioning a larger-than-expected loss. Altogether, a series of regulatory, legal and payment-network signals built up on one timeline. ## Analyst Ratings Sixteen brokers cover HIMS.US: 1 rates it buy, 2 rate it overweight, 11 rate it hold, 1 rates it underweight, and 1 has no opinion; none rate it sell. The consensus rating is hold, with a consensus target of $31.23, about 8.29% above spot. Targets range from $23.00 to $42.00, showing wide dispersion. Within its industry, the stock ranks 10th out of 53 healthcare-services names, placing it in the upper-middle tier. ## The Week Ahead Next week is heavy on US macro data. Monday brings the Dallas Fed manufacturing activity index. Tuesday has the S&P Global manufacturing PMI final, ISM manufacturing PMI and JOLTS job openings; ISM is forecast at 55.2 versus 55.6, and JOLTS at 7.3 versus 7.359. Wednesday includes ADP private payrolls, factory orders and EIA crude inventories. HIMS.US has no confirmed earnings date on the calendar, but this week’s open threads, the FTC suit, Visa monitoring and the fraud investigation, are likely to move on any further signals from regulators or the payment network. ## In Short The week’s tension sits between regulatory pressure and valuation. The consensus rating is hold and the consensus target is still about 8.29% above spot, but the stock trades at roughly 20.76x book with negative trailing earnings, a rich valuation. On the latest trading day, large and medium orders were net sellers while small orders were net buyers, so money flow was split. With Visa’s monitoring and the FTC suit unresolved, price sensitivity to negative headlines looks amplified. What matters next is the substance of the investigations, whether the payment channel tightens further, and whether fund flow moves from divergence to a clearer direction. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [HIMS.US](https://longbridge.com/en/quote/HIMS.US.md) - [HIMZ.US](https://longbridge.com/en/quote/HIMZ.US.md) - [HIYY.US](https://longbridge.com/en/quote/HIYY.US.md) ## Related News & Research - [Hims & Hers Chief Legal Officer Soleil Boughton disposes of 3,461 common shares worth $100,964.37](https://longbridge.com/en/news/300825825.md) - [Hims & Hers Health (HIMS) Is Up 13.8% After FTC Suit And AI Weight-Loss Launch - Has The Bull Case Changed?](https://longbridge.com/en/news/295313745.md) - [Hims & Hers CFO Oluyemi Okupe sells 29,277 common shares for $876,846.15](https://longbridge.com/en/news/299939486.md) - [Hims & Hers CTO Mohamed Elshenawy sells 7,954 shares worth $225,421.06](https://longbridge.com/en/news/299360969.md) - [Hims & Hers stock plunges after FTC sues over alleged privacy violations](https://longbridge.com/en/news/294240792.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**